Online inquiry

IVTScrip™ mRNA-Anti-GP6, ACT-017(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1649MR)

This product GTTS-WQ1649MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets GP6 gene. The antibody can be applied in Ischemic stroke research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001083899.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 51206
UniProt ID Q9HCN6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GP6, ACT-017(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1649MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9530MR IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA J-591
GTTS-WQ1829MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AFD Anti-fD
GTTS-WQ8337MR IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HN-66000
GTTS-WQ14451MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ13803MR IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN-10933
GTTS-WQ5552MR IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CDP7657
GTTS-WQ292MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ5083MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CAM-3001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW